Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
27 Setembro 2023 - 5:30PM
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS),
a clinical-stage biotechnology company using its pioneering
gene-editing platform to develop life-saving cell and gene
therapies, announced today that pre-clinical data on MUC1-CAR
T-cells to overcome key challenges of targeting solid tumors, will
be presented at the Society for Immunotherapy of Cancer’s 38th
Annual Meeting (SITC 2023), that will take place on November 1-5,
2023 at San Diego Convention Center in San Diego (CA).
Poster Presentation:
Laurent Poirot, SVP Immunology of Cellectis,
will present a poster on the benefits of combining potency
attributes for TALEN®-edited smart CAR T-cells targeting MUC1 in
preclinical models of triple-negative breast cancer.
Title: TGF-Beta Blockade
Combined with Activation-Induced IL12 Secretion Synergize to
Optimize Potency of MUC1-CAR T-cells in Preclinical Targeting of
Triple-Negative Breast Cancer.
Poster Number: 254
Presenter: Laurent Poirot, Ph.D., SVP
Immunology, Cellectis.
Date/Time: Poster will be on
display Saturday, November 4th, 2023 from 9:00 a.m. to 8:30 p.m.
PDT, at San Diego Convention Center, Hall A.
Full text of the abstract will be made public on
October 31, 2023 at 9:00 a.m. EDT on the SITC website and in a
Journal for ImmunoTherapy of Cancer (JITC) supplement
published on Oct. 31st, 2023 at 6 a.m. PDT/9 a.m. EDT.
About Cellectis
Cellectis is a clinical-stage biotechnology
company using its pioneering gene-editing platform to develop
life-saving cell and gene therapies. Cellectis utilizes an
allogeneic approach for CAR-T immunotherapies in oncology,
pioneering the concept of off-the-shelf and ready-to-use
gene-edited CAR T-cells to treat cancer patients, and a platform to
make therapeutic gene editing in hemopoietic stem cells for various
diseases. As a clinical-stage biopharmaceutical company with over
23 years of experience and expertise in gene editing, Cellectis is
developing life-changing product candidates utilizing TALEN®, its
gene editing technology, and PulseAgile, its pioneering
electroporation system to harness the power of the immune system in
order to treat diseases with unmet medical needs. Cellectis’
headquarters are in Paris, France, with locations in New York, New
York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq
Global Market (ticker: CLLS) and on Euronext Growth (ticker:
ALCLS).
Forward-looking Statements
This press release contains “forward-looking”
statements within the meaning of applicable securities laws,
including the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by words such as
“anticipate,” “expect,” “plan,” “could” and “will,” or the negative
of these and similar expressions. These forward-looking statements,
which are based on our management’s current expectations and
assumptions and on information currently available to management,
include statements about the potential benefit of the Company’s
candidate products. These forward-looking statements are made in
light of information currently available to us and are subject to
numerous risks and uncertainties, including with respect to the
numerous risks associated with biopharmaceutical product candidate
development. With respect to our cash runway, our operating plans,
including product development plans, may change as a result of
various factors, including factors currently unknown to us.
Furthermore, many other important factors, including those
described in our Annual Report on Form 20-F and the financial
report (including the management report) for the year ended
December 31, 2022 and subsequent filings Cellectis makes with the
Securities Exchange Commission from time to time, as well as other
known and unknown risks and uncertainties may adversely affect such
forward-looking statements and cause our actual results,
performance or achievements to be materially different from those
expressed or implied by the forward-looking statements. Except as
required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
For further information on Cellectis, please
contact:
Media contact:
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77
46 93, media@cellectis.com
Investor Relations contacts:
Arthur Stril, Chief Business Officer, +1 (347) 809 5980,
investors@cellectis.com
Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577
- SITC_2023_curtain raiser_PR
Cellectis (NASDAQ:CLLS)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Cellectis (NASDAQ:CLLS)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024